EE186 Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.570
https://www.valueinhealthjournal.com/article/S1098-3015(25)03127-4/fulltext
Title :
EE186 Cost per Responder of TAR-200 vs. Other FDA-Approved Novel and Generic Treatments Among Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer With Carcinoma in Situ in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)03127-4&doi=10.1016/j.jval.2025.09.570
First page :
Section Title :
Open access? :
No
Section Order :
10159